Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy.

Chen H, Luan X, Paholak HJ, Burnett JP, Stevers NO, Sansanaphongpricha K, He M, Chang AE, Li Q, Sun D.

Nanomedicine (Lond). 2020 Jan;15(1):77-92. doi: 10.2217/nnm-2019-0190.

PMID:
31868112
2.

Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.

Burnett JP, Lim G, Li Y, Shah RB, Lim R, Paholak HJ, McDermott SP, Sun L, Tsume Y, Bai S, Wicha MS, Sun D, Zhang T.

Cancer Lett. 2017 May 28;394:52-64. doi: 10.1016/j.canlet.2017.02.023. Epub 2017 Feb 27.

PMID:
28254410
3.

Elimination of epithelial-like and mesenchymal-like breast cancer stem cells to inhibit metastasis following nanoparticle-mediated photothermal therapy.

Paholak HJ, Stevers NO, Chen H, Burnett JP, He M, Korkaya H, McDermott SP, Deol Y, Clouthier SG, Luther T, Li Q, Wicha MS, Sun D.

Biomaterials. 2016 Oct;104:145-57. doi: 10.1016/j.biomaterials.2016.06.045. Epub 2016 Jun 23.

4.

Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options.

Burnett JP, Korkaya H, Ouzounova MD, Jiang H, Conley SJ, Newman BW, Sun L, Connarn JN, Chen CS, Zhang N, Wicha MS, Sun D.

Sci Rep. 2015 Nov 2;5:15821. doi: 10.1038/srep15821.

5.

CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.

Conley SJ, Baker TL, Burnett JP, Theisen RL, Lazarus D, Peters CG, Clouthier SG, Eliasof S, Wicha MS.

Breast Cancer Res Treat. 2015 Apr;150(3):559-67. doi: 10.1007/s10549-015-3349-8. Epub 2015 Apr 2.

PMID:
25833208
6.

Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions.

Jiang Y, Bernard D, Yu Y, Xie Y, Zhang T, Li Y, Burnett JP, Fu X, Wang S, Sun D.

J Biol Chem. 2010 Jul 2;285(27):21023-36. doi: 10.1074/jbc.M110.103390. Epub 2010 Apr 22.

7.

A serological study of Dirofilaria immitis in feral cats in Grenada, West Indies.

Fernandez C, Chikweto A, Mofya S, Lanum L, Flynn P, Burnett JP, Doherty D, Sharma RN.

J Helminthol. 2010 Dec;84(4):390-3. doi: 10.1017/S0022149X10000027. Epub 2010 Feb 10.

PMID:
20144260
8.

Characterization of the neuropeptide Y5 receptor in the human hypothalamus: a lack of correlation between Y5 mRNA levels and binding sites.

Statnick MA, Schober DA, Gackenheimer S, Johnson D, Beavers L, Mayne NG, Burnett JP, Gadski R, Gehlert DR.

Brain Res. 1998 Nov 9;810(1-2):16-26.

PMID:
9813224
9.

Sulphur-containing amino acids are agonists for group 1 metabotropic receptors expressed in clonal RGT cell lines.

Kingston AE, Lowndes J, Evans N, Clark B, Tomlinson R, Burnett JP, Mayne NG, Cockerham SL, Lodge D.

Neuropharmacology. 1998;37(3):277-87.

PMID:
9681926
10.

LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors.

Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, Belagaje R, Wu S, Schoepp DD.

Neuropharmacology. 1998;37(1):1-12.

PMID:
9680254
11.

The expression of voltage-dependent calcium channel beta subunits in human cerebellum.

Volsen SG, Day NC, McCormack AL, Smith W, Craig PJ, Beattie RE, Smith D, Ince PG, Shaw PJ, Ellis SB, Mayne N, Burnett JP, Gillespie A, Harpold MM.

Neuroscience. 1997 Sep;80(1):161-74.

PMID:
9252229
12.

Preparation and purification of antibodies specific to human neuronal voltage-dependent calcium channel subunits.

Beattie RE, Volsen SG, Smith D, McCormack AL, Gillard SE, Burnett JP, Ellis SB, Gillespie A, Harpold MM, Smith W.

Brain Res Brain Res Protoc. 1997 Aug;1(3):307-19.

PMID:
9385070
13.

LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors.

Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Mayne NG, Wu S, Cockerman SL, Burnett JP, Belegaje R, Bleakman D, Monn JA.

Neuropharmacology. 1997 Jan;36(1):1-11.

PMID:
9144636
14.

Analysis of NPY receptor subtypes in the human frontal cortex reveals abundant Y1 mRNA and binding sites.

Statnick MA, Schober DA, Mayne NG, Burnett JP, Gehlert DR.

Peptides. 1997;18(1):137-43.

PMID:
9114463
15.

The neuropeptide Y Y1 receptor selective radioligand, [125I][Leu31,Pro34]peptide YY, is also a high affinity radioligand for human pancreatic polypeptide 1 receptors.

Gehlert DR, Gackenheimer SL, Schober DA, Beavers L, Gadski R, Burnett JP, Mayne N, Lundell I, Larhammar D.

Eur J Pharmacol. 1996 Dec 30;318(2-3):485-90.

PMID:
9016942
17.

(2S,4S)-2-amino-4-(4,4-diphenylbut-1-yl)- pentane-1,5-dioic acid: a potent and selective antagonist for metabotropic glutamate receptors negatively linked to adenylate cyclase.

Wermuth CG, Mann A, Schoenfelder A, Wright RA, Johnson BG, Burnett JP, Mayne NG, Schoepp DD.

J Med Chem. 1996 Feb 16;39(4):814-6. No abstract available.

PMID:
8632404
19.
20.

Pharmacological analysis of 4-carboxyphenylglycine derivatives: comparison of effects on mGluR1 alpha and mGluR5a subtypes.

Kingston AE, Burnett JP, Mayne NG, Lodge D.

Neuropharmacology. 1995 Aug;34(8):887-94.

PMID:
8532170
21.

Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4- dicarboxylate.

Schoepp DD, Johnson BG, Salhoff CR, Valli MJ, Desai MA, Burnett JP, Mayne NG, Monn JA.

Neuropharmacology. 1995 Aug;34(8):843-50.

PMID:
8532165
23.
24.
25.

Cyclothiazide potentiates agonist responses at human AMPA/kainate receptors expressed in oocytes.

Sharp RL, May PC, Mayne NG, Snyder YM, Burnett JP.

Eur J Pharmacol. 1994 Jan 1;266(1):R1-2.

PMID:
7511109
26.

Cytoplasmic inclusion bodies in Escherichia coli producing biosynthetic human insulin proteins.

Williams DC, Van Frank RM, Muth WL, Burnett JP.

Science. 1982 Feb 5;215(4533):687-9.

PMID:
7036343
27.
28.

Retention of tumour-inducing capacity by adenovirus DNA after cleavage by restriction endonucleases.

Burnett JP, Mayne N, Helton L.

Nature. 1975 Mar 13;254(5496):158-9. No abstract available.

PMID:
1090847
29.

Base composition and hybridization studies of the three double-stranded RNA segments of bacteriophage phi 6.

Van Etten JL, Vidaver AK, Koski RK, Burnett JP.

J Virol. 1974 Jun;13(6):1254-62.

30.

Binding of ethidium bromide to double-stranded ribonucleic acid.

Douthart RJ, Burnett JP, Beasley FW, Frank BH.

Biochemistry. 1973 Jan 16;12(2):214-20. No abstract available.

PMID:
4630220
31.

On the mycophage of Penicillium chrysogenum.

Nash CH, Douthart RJ, Ellis LF, Van Frank RM, Burnett JP, Lemke PA.

Can J Microbiol. 1973 Jan;19(1):97-103. No abstract available.

PMID:
4631050
32.

Chemical and physical relationships of oncogenic and non-oncogenic simian adenovirus DNA's.

Burnett JP, Mayne N, Butler LK, Harrington JA.

J Gen Virol. 1972 Dec;17(3):245-53. No abstract available.

PMID:
4631142
33.

Tumour induction by simian adenovirus SA7 DNA fragments.

Mayne N, Burnett JP, Butler LK.

Nat New Biol. 1971 Aug 11;232(2):182-3. No abstract available.

PMID:
5285272
34.

Infectivity associated with Simian adenovirus type SA7 DNA.

Burnett JP, Harrington JA.

Nature. 1968 Dec 21;220(5173):1245. No abstract available.

PMID:
5725987
35.

Production of highly labeled adenoviruses.

Burnett JP, Summers AO, Harrington JA, Dwyer AC.

Appl Microbiol. 1968 Aug;16(8):1245-50.

36.

Simian adenovirus SA7 DNA: chemical, physical, and biological studies.

Burnett JP, Harrington JA.

Proc Natl Acad Sci U S A. 1968 Jul;60(3):1023-9. No abstract available.

37.

THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS.

JOHNSON IS, ARMSTRONG JG, GORMAN M, BURNETT JP Jr.

Cancer Res. 1963 Sep;23:1390-427. Review. No abstract available.

38.

Formation of hemoglobin in the presence of 3H-L-valyl-L-leucine.

BURNETT JP Jr, HAUROWITZ F.

Hoppe Seylers Z Physiol Chem. 1963 Mar;331:67-76. No abstract available.

PMID:
14017137
39.

Composition of antibodies against acidic and basic azoproteins.

FLEISCHER S, HARDIN RL, HOROWITZ J, ZIMMERMAN M, GRESHAM E, TURNER JE, BURNETT JP Jr, STARY Z HAUROWITZ F.

Arch Biochem Biophys. 1961 Feb;92:329-32. No abstract available.

PMID:
13700185

Supplemental Content

Loading ...
Support Center